Aevit

Quick links to important sections

Aevit

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aevit

Property Description
Active ingredients Retinol (Vitamin A) and Alpha-Tocopherol (Vitamin E)
Form Soft capsules containing an oil solution
Pharmacological class Combined vitamin preparations, Fat-Soluble Vitamins
General use Management of combined vitamin deficiency (Hypovitaminosis)
Origin Combination of synthetic and/or derived natural chemical substances

What Type of Medicine is Aevit? (Definition and Classification)

Aevit is a therapeutic combined vitamin preparation defined as a fixed-dose combination of the essential fat-soluble vitamins, Retinol (Vitamin A) and Alpha-Tocopherol (Vitamin E). This combination delivers high-potency vitamins, distinguishing it from general daily supplements, and is classified within the pharmacological group of Fat-Soluble Vitamins. The simultaneous use of Retinol and Alpha-Tocopherol provides synergistic antioxidant interactions against lipid peroxidation in cellular systems. These two components protect cellular fats more effectively together than when utilized separately.

Aevit's Composition: Retinol and Alpha-Tocopherol

The specific formulation of Aevit uses Retinol palmitate (Vitamin A) and Alpha-Tocopherol Acetate (Vitamin E), stabilized ester derivatives presented for oral use typically within soft capsules containing an oil solution. This fat-soluble delivery system is a key feature, as its absorption is specifically optimized by the presence of the vegetable oil base. Aevit is primarily differentiated by its dual focus on tissue regeneration (via Retinol) and robust cellular protection (via Alpha-Tocopherol), a combined mandate often necessary in the complex therapy of certain chronic conditions.

General Purpose: Support for Deficiency and Cellular Health

The general therapeutic purpose of Aevit is to compensate for a combined deficiency (hypovitaminosis) of both Vitamin A and Vitamin E. The formulation supports two main actions: Alpha-Tocopherol acts as a radical scavenger to safeguard the integrity of cell membranes, while Retinol is essential for tissue regeneration and the healthy functioning of skin and mucous membranes. This combined action supports normal metabolism and helps maintain structural and functional integrity across multiple body systems.

Regulatory References

  1. Vitamins: MedlinePlus Medical Encyclopedia

What side effects are possible with Aevit?

The safety profile of Aevit is governed by the risk of accumulation of its fat-soluble components, Retinol (Vitamin A) and Alpha-Tocopherol (Vitamin E), which can lead to toxicity, particularly with chronic, high-dose exposure. The information below is based on adverse event classifications and safety constraints documented in official government regulatory sources.

Documented Adverse Reactions by System-Organ Class

Adverse reactions are formally grouped by the affected body system according to regulatory standards:

  • Gastrointestinal Disorders: Common effects include Nausea, Vomiting, and Abdominal discomfort.
  • Nervous System Disorders: Reactions may include Headache and Dizziness.
  • Skin and Subcutaneous Tissue Disorders: Prolonged high intake is associated with effects like Dry skin or Alopecia (hair loss).
  • Immune System Disorders: Hypersensitivity and allergic reactions, including rare cases of Anaphylaxis, are documented.

Critical Safety Constraints and Serious Effects

The most significant safety constraint is the potential for Hypervitaminosis A (excess Vitamin A) with long-term use. Serious adverse reactions documented in regulatory text include:

  • Increased intracranial pressure (Pseudotumor cerebri).
  • Bone pain and Joint pain (Musculoskeletal disorders).
  • Risk of Increased bleeding associated with very high doses of Alpha-Tocopherol.

Population-Specific Safety Considerations

High-dose Retinol is officially classified as a teratogen in regulatory documents. Therefore, use is strictly contraindicated during pregnancy due to the risk of fetal malformations. Caution is also required in individuals with Hepatic impairment or a pre-existing state of Hypervitaminosis A, as the liver is the primary storage site for these fat-soluble vitamins.

Overdose and Emergency Response

The overdose profile for Aevit is defined by the distinct toxicities of its components, Retinol (Vitamin A) and Alpha-Tocopherol (Vitamin E). The risk of Hypervitaminosis A can result from either a single, very high dose (acute) or prolonged high-dose intake (chronic).

Acute toxicity may present with symptoms such as severe headache, nausea, and vomiting. Chronic toxicity is documented to cause manifestations like hair loss (alopecia), dry and rough skin, and joint pain (arthralgia). Overdose of the Alpha-Tocopherol component is chiefly associated with an increased risk of bleeding or coagulopathy.

Severe outcomes explicitly listed in regulatory documents include life-threatening effects on the central nervous system, such as increased intracranial pressure (pseudotumor cerebri), and severe liver damage (cirrhosis) from chronic exposure. In the event of an overdose, management is supportive and requires the discontinuation of the medicine, as no specific antidote is known for Retinol toxicity.

When to Seek Help: Seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the individual is unresponsive, has a seizure, is experiencing trouble breathing, or has collapsed. Official warnings also note that pregnant women face a documented risk of birth defects due to Retinol toxicity.

Therapeutic Uses of Aevit

Aevit is used to help manage symptoms linked to a shortage of Vitamin A and Vitamin E. This medicine is intended to assist in the management of symptoms associated with these specific vitamin shortages, which may be observed in situations of elevated physical or mental demand, stress, poor or unbalanced diets, or during recovery from prolonged illnesses. The product is administered when there is a documented deficiency or a higher requirement for these nutrients.

Common clinical scenarios of use involve addressing Vitamin A and E hypo- or avitaminosis, as well as situations involving an increased demand for the vitamins, such as in states of asthenia (weakness or lack of energy). The medication is indicated for A and E hypo-/avitaminosis, and conditions of vitamin A and E higher demand and/or their lower supply due to diet or other factors. The benefit for the patient is the potential for assistance with symptom relief and support for functions dependent on these nutrients.

“The combination of these vitamins may offer support in addressing deficiency-related symptoms.”

This information is consistent with the general therapeutic classifications for these nutrients.

Eligibility and Restrictions for Use

Eligibility Scope

Aevit's use is strictly defined by regulatory documents, limiting the population due to the high concentration of fat-soluble vitamins, primarily Retinol.

Eligibility Status Defined Populations (Per Regulatory Label)
Allowed Adults with documented Vitamin A and E hypo-/avitaminosis (deficiency).
Contraindicated (Must NOT Use) Patients with hypersensitivity to ingredients or pre-existing Hypervitaminosis A. Also, those with severe chronic heart failure, sarcoidosis, chronic nephritis, cholecystitis, or chronic pancreatitis.
Age and Reproductive Restrictions Contraindicated during the first trimester of pregnancy and generally not recommended during the second/third trimesters or lactation. Use is contraindicated for children under 14 years of age.
Conditional Use Patients with severe atherosclerosis, severe hepatic or renal impairment, or those at an increased risk of thromboembolism require cautious, restricted, or monitored use.

Resulting Eligibility Structure

This eligibility profile establishes absolute non-eligibility for high-risk groups to prevent serious complications, particularly those related to Vitamin A toxicity and pre-existing organ disease. The official statements thus strictly limit the medicine to adults seeking management for documented combined vitamin deficiency, and mandate caution in the older adult population.

What should I know about interactions with other medicines?

This section details the officially documented interaction patterns for Aevit, based on regulatory labeling for its active components, Retinol (Vitamin A) and Alpha-Tocopherol (Vitamin E).

The regulatory profile establishes key contraindicated combinations. Vitamin A must not be combined with other systemic retinoids (such as Isotretinoin) due to the documented risk of aggravating Hypervitaminosis A. Co-administration with Tetracycline-class antibiotics is also advised to be avoided because of the risk of Intracranial Hypertension.

A significant pharmacodynamic interaction is noted for Vitamin E, which is officially described as having anti-vitamin K effects. This action may potentiate the effect of oral anticoagulants like Warfarin, increasing the potential for hemorrhage. This risk requires caution and is heightened in patient populations with underlying Vitamin K deficiencies.

Interactions that alter systemic exposure are also documented. Drugs that reduce fat absorption, such as Orlistat and Mineral Oil, significantly decrease Vitamin E absorption, creating a mandatory timing rule where Orlistat must be administered two hours apart from Vitamin E. Conversely, oral contraceptives are documented to result in an increase in Vitamin A plasma levels. Certain anticonvulsants may also officially lower Vitamin E levels.

Mechanism of Action

Aevit is a fixed-dose combination of Vitamin A (Retinol) and Vitamin E (Alpha-tocopherol), which modulate cellular processes through distinct, synergistic pathways.

Modulation of Gene Expression

Vitamin A, through its active metabolite, retinoic acid, functions as a ligand for nuclear receptors, specifically the Retinoic Acid Receptors (RAR) and Retinoid X Receptors (RXR). The resulting ligand-receptor complex acts as a transcription factor, modifying the expression of target genes involved in cellular differentiation, epithelial integrity, and immune cell signaling. This process influences fundamental cellular morphology and maintenance.


Direct Antioxidant Activity

Vitamin E is a lipid-soluble antioxidant that incorporates into cell membranes. It functions by directly scavenging reactive oxygen species and free radicals, particularly lipid peroxyl radicals. This interaction terminates the chain reaction of lipid peroxidation, thereby stabilizing membrane fluidity and integrity against oxidative stress.


Redox Pathway Interplay

This combination establishes a redox cycle where Vitamin E chemically stabilizes and spares Vitamin A from oxidative destruction. Together, they modulate signaling cascades associated with tissue metabolism and cellular respiration, influencing the balance of cellular oxidative processes.

Dosage and Administration Information

How to Use Aevit: Administration Guidelines

This section outlines the administration protocol for Aevit, a fixed-dose combination of Vitamin A (Retinol) and Vitamin E (Alpha-Tocopherol).


Administration Protocol

The established regimen is governed by a fixed, oral daily dose intended for adults. The therapeutic schedule involves taking one capsule once per day. Each capsule provides a high-concentration dose, specifically 100,000 IU of Retinol palmitate and 100 mg of Alpha-Tocopherol acetate.

For proper administration, the soft capsule must be swallowed whole with water and should not be chewed or crushed. Due to the nature of its components, it is typically taken with or immediately following a meal to enhance the absorption of the fat-soluble vitamins.


Usage Constraints and Duration

The usage of Aevit is subject to time-limited constraints. The course of administration is defined as a short, finite duration, usually lasting between 20 to 40 days. Administration is stopped after the course is completed, and a mandated break is required before considering any subsequent repeat course. The daily dose is not to be exceeded.

Detail Instruction
Route of administration Oral (Capsule intake)
Frequency pattern Once daily
Age-group use Intended for adult use only
Time-limited use Short courses of 20 to 40 days

This structured protocol ensures that the medicine is administered according to high-potency dosing parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aevit (Retinol and Alpha-Tocopherol)

The research landscape for the combination of Retinol (Vitamin A) and Alpha-Tocopherol (Vitamin E) includes various study types, such as controlled trials, systematic reviews, and mechanistic laboratory research. This evidence was studied for its role in addressing vitamin shortages and for its intrinsic biological actions.


Evidence for Management of Combined Vitamin A and E Deficiency (Hypovitaminosis)

Research was evaluated in studies that focus on the general use of these nutrients to address a confirmed or anticipated shortage of both Vitamin A and Vitamin E. The evidence base includes randomized controlled trials (RCTs) and meta-analyses that were observed in populations experiencing dual vitamin deficiency, often due to underlying health issues.

Researchers primarily monitored how serum/plasma concentrations changed during supplementation, which are outcomes monitoring physiological strain or stress. Findings describe patterns observed in the studies related to changes in these blood biomarkers during the period of vitamin provision. Many of these findings were mixed and often derived from studies that examined the vitamins individually or as part of broader multi-nutrient formulas. Consequently, the certainty remains low regarding the generalized outcomes of this specific fixed-dose formulation.


Understanding the Biochemical Basis in Research

This part covers the mechanistic research that was studied for the biochemical activity that forms the rationale for the fixed combination. Laboratory investigations, which utilized in vitro and animal models, explored the interaction between Retinol and Alpha-Tocopherol. These studies monitored outcomes related to the protection of cellular fats from oxidative damage. Laboratory research describes patterns of lipid stability that were observed in the presence of both vitamins. It is not yet clear whether this mechanism translates into measurable clinical benefit for specific diseases in humans.


Evidence Gaps and Areas of Research Uncertainty

Comparative evidence is lacking to show whether this fixed-dose product offers any functional advantage over separate vitamin supplements or other multivitamin formulations. Furthermore, the follow-up durations were limited in many core studies, and long-term effects are not fully established regarding the consistency of biochemical changes over many years. Data for certain groups remain insufficient, particularly in broad special populations like those with common comorbid conditions.

Key Studies & References

  1. Human Vitamin E Deficiency, and what is and is NOT vitamin E?
  2. Abetalipoproteinemia - Symptoms, diagnosis and treatment | BMJ Best Practice US (Citing small studies/case reports)
  3. Abetalipoproteinemia - GeneReviews® - NCBI Bookshelf (Addressing vitamin A and E therapy in rare disorders)
  4. Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa (ClinicalTrials.gov ID NCT00000114)

Frequently Asked Questions (FAQ)

Common questions about Aevit (FAQ)


Q: What is the main difference between Aevit and regular vitamin pills?

A: Aevit is defined in official documents as a therapeutic, fixed-dose combination of high-potency fat-soluble vitamins. This classification distinguishes it from general daily vitamin supplements, as it is intended for use in documented combined deficiency (hypovitaminosis) of Vitamin A and E.


Q: Is Aevit considered a long-term supplement or a short-course treatment?

A: According to the official product information, Aevit administration is subject to strict time-limited constraints. It is defined as a short, finite course of treatment, typically lasting between 20 to 40 days.


Q: What is the typical duration of treatment with Aevit?

A: Regulatory documents state that the course of administration for Aevit is usually lasting between 20 to 40 days.


Q: Do you need to cycle on and off Aevit, or can it be continuous?

A: The official product labeling indicates that administration is stopped after the course is completed and a mandated break is specified before any subsequent repeat course is considered.


Q: What is the risk of developing a vitamin surplus with Aevit?

A: Because the active components are fat-soluble (Vitamins A and E), there is a risk of accumulation in the body. This accumulation, particularly with chronic high-dose exposure, can lead to a state of toxicity known as Hypervitaminosis A.


Q: Does Aevit have a risk of overdose, and what are the signs?

A: The risk of overdose is related to the potential for Hypervitaminosis A, or excess Vitamin A. Documented serious effects linked to high-dose toxicity include increased intracranial pressure, bone pain, and joint pain. These effects are described as critical safety constraints in official documents.


Q: What is the connection between Aevit and eyesight or vision health?

A: The active ingredient Retinol (Vitamin A) is officially described as essential for the healthy functioning of the skin and mucous membranes. It is also known to be required for normal vision.


Q: Can men and women use Aevit for the same purposes?

A: Aevit is intended for adult use to compensate for combined Vitamin A and E deficiency. The primary population-specific use constraints are related only to pregnancy and lactation in women.


Q: Is Aevit intended for acute treatment or for deficiency prevention?

A: The general therapeutic purpose of Aevit is to compensate for a combined deficiency (hypovitaminosis) of both Vitamin A and Vitamin E.


Q: Why do some sources mention Aevit as an antioxidant?

A: The Alpha-Tocopherol (Vitamin E) component is officially described as a lipid-soluble antioxidant. It functions to protect cell membranes against oxidative stress and free radicals.


Q: How is the potency of Aevit measured (e.g., in IU or milligrams)?

A: The potency of the Vitamin A component (Retinol) is commonly expressed in International Units (IU) in the product labeling, a recognized unit of measure. The Vitamin E component (Alpha-Tocopherol) is generally expressed in milligrams (mg).


Q: Are there different strengths or forms of Aevit available?

A: Aevit is defined as a fixed-dose combination. The standard therapeutic schedule involves a single, fixed capsule dose per day, which provides specific, unchanging amounts of Retinol palmitate and Alpha-Tocopherol acetate.


Q: What are the potential interactions with certain antibiotics?

A: Regulatory labeling advises avoiding co-administration with Tetracycline-class antibiotics. This caution relates to the documented risk of increased intracranial pressure when these drug types are combined.


Q: Can Aevit be taken alongside hormonal contraceptives?

A: Official documents state that taking oral contraceptives is documented to result in an increase in Vitamin A plasma levels. This is noted as an interaction pattern to be aware of.


Q: Does Aevit have any known effect on liver function?

A: Caution is officially advised for use in patients with pre-existing hepatic impairment, or reduced liver function. This is because the liver is the primary storage site for these fat-soluble vitamins.


Q: What if I take another multivitamin that also contains Vitamin A and E?

A: Official documents caution against use if a pre-existing state of Hypervitaminosis A is already present. This is due to the potential for excessive accumulation of fat-soluble vitamins, which can lead to toxicity.


Q: Is it normal to feel slightly nauseous when first starting Aevit?

A: Official documents list Nausea as a common documented adverse reaction grouped under Gastrointestinal Disorders. Abdominal discomfort and vomiting are also noted among possible effects.


Q: What are the signs that Aevit is not being tolerated well?

A: Official safety documents list potential signs of intolerance, including documented adverse reactions such as nausea, vomiting, abdominal discomfort, headache, and dizziness.


Q: Are there any official reports of serious reactions to Aevit?

A: Regulatory documents list and classify serious adverse reactions, such as increased intracranial pressure and increased bleeding, which are subject to official surveillance and reporting processes.


Q: Are there any documented cases of long-term problems from Aevit use?

A: The most significant safety constraint documented with long-term use is the potential for Hypervitaminosis A (excess Vitamin A). This condition is associated with serious health effects.


Q: Is the research evidence for Aevit considered strong or limited?

A: The research evidence overview indicates that findings related to the fixed-dose combination were often mixed. Studies often had limited follow-up durations, suggesting that certainty remains low regarding generalized long-term outcomes for specific diseases in humans.

How should Aevit be stored and disposed of?

How to Store and Dispose of Aevit?

Official regulatory documents define strict conditions for the storage and disposal of Aevit to maintain the stability of its components, Vitamin A and Vitamin E.

Storage Requirements

The product must be stored at a temperature not exceeding 25 C and should not be frozen. The capsules must be protected from light and moisture and kept in their original container, with the lid tightly closed. As with all medicines, Aevit must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Aevit must be disposed of in accordance with local requirements for pharmaceutical waste. The product must not be discarded via household wastewater (e.g., flushed down the toilet) to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aevit found in:

A-Z Index: